Monitor the ASCO presentation on June 1 for initial clinical activity and safety signals in the azenosertib-paclitaxel arm. While this is not a pivotal readout, positive data could expand azenosertib’s franchise potential beyond monotherapy and support future combination strategies.
Price Chart
Executive Summary
Zentalis Pharmaceuticals announced that data from Part 1 of its MUIR trial, evaluating azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, will be presented at the 2026 ASCO Annual Meeting. While the abstract acceptance signals growing clinical interest, no efficacy or safety data are being released yet, and the event is informational rather than data-driven.
Key Facts
- Abstract on azenosertib + paclitaxel in platinum-resistant ovarian cancer accepted for poster presentation at ASCO 2026.
- Presentation scheduled for June 1, 2026, during the Gynecologic Cancer poster session.
- Data to be presented are from Part 1 of the Phase 1b MUIR trial, focusing on safety and preliminary activity.
- Azenosertib remains in late-stage development as monotherapy for Cyclin E1-positive PROC, with pivotal DENALI and ASPENOVA trials ongoing.
- Azenosertib has Fast Track Designation from the FDA for Cyclin E1-positive platinum-resistant ovarian cancer.
Financial Impact
No immediate financial impact; potential future upside if data support registrational path for combination use.
Risk Factors
- Interim or preliminary data may not translate into meaningful clinical benefit.
- Combination regimens may face higher safety hurdles or limited differentiation from existing therapies.
- Zentalis remains dependent on a single asset (azenosertib) with no approved products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278159 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.52 (+31.98%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.52 (+29.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.52 (−32.80%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.52 (−36.20%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.52 (−36.84%) |
Apr 17, 2026 24w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.52 (−45.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access